Nuvo Research reaches another milestone with the launch of Pliaglis in Europe

Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology. Marketing licenses have been issued in 14 of the 16 European countries which are listed in the European Marketing Application for Pliaglis.

“The launch of Pliaglis in the E.U. is yet another important and exciting milestone for Nuvo”

Pliaglis is a topical local anesthetic cream that uses Nuvo's proprietary phase-changing technology to form a pliable peel on the skin when exposed to air. In the E.U. Pliaglis is indicated in adults to produce local dermal anaesthesia on intact skin prior to dermatological procedures.

Galderma launched Pliaglis in Argentina in 2011 and in the U.S. in March 2013 and anticipates that it will launch in Canada and a number of Central American, South American and Asian countries in 2014 and 2015.

"We are proud in being able to bring additional comfort to patients in Aesthetic treatments," said Mr. Didier Leclercq, Managing Director of Galderma Aesthetic & Corrective Center of Excellence. "Pliaglis really sets a new standard in topical anesthetics, and is a great complementary product in our already comprehensive Aesthetic portfolio in Europe. "

"The launch of Pliaglis in the E.U. is yet another important and exciting milestone for Nuvo," said Dr. Bradley Galer, President of Nuvo's Pain Group. "Galderma has an excellent launch plan for the countries of Europe to introduce the benefits of Pliaglis to physicians who provide aesthetic services to their patients."

Source:

Nuvo Research Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Cannabidiol and the shifting perspective of epilepsy drug discovery